This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Ocrelizumab is a monoclonal antibody directed at CD20, a membrane glycosylated phosphoprotein found predominately on B-lymphocytes, but not plasma cells or neutrophils, which has shown efficacy in treatment of relapsing and primary progressive multiple sclerosis (MS). In phase 3 clinical trials, infusion reactions, infections, and a small number of malignancies were found more frequently with ocrelizumab than placebo. IV administration results in rapid depletion of pre-B and mature B-lymphocytes.1 Ocrelizumab, administered every 6 months, was approved for treatment of MS in the United States in March 2017, and is closely related in structure and mechanism of action to rituximab, used for many years in treatment of rheumatoid arthritis. As of August 2018, the manufacturer reports >61,800 people have received ocrelizumab postmarketing, and >3,800 in clinical trials.
Footnotes
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the author, if any, are provided at the end of the article.
- Received July 10, 2018.
- Accepted in final form December 14, 2018.
- © 2019 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
- Reader response: Late-onset neutropenia following ocrelizumab therapy for multiple sclerosis
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Alert Me
Recommended articles
Lymphocyte reconstitution after DMF discontinuation in clinical trial and real-world patients with MS
Effect of dimethyl fumarate on lymphocytes in RRMS
Characterizing absolute lymphocyte count profiles in dimethyl fumarate–treated patients with MS
Monitoring B-cell repopulation after depletion therapy in neurologic patients